These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 35303157)

  • 21. True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature.
    Nicolazzo C; Barault L; Caponnetto S; De Renzi G; Belardinilli F; Bottillo I; Bargiacchi S; Macagno M; Grammatico P; Giannini G; Cortesi E; Di Nicolantonio F; Gazzaniga P
    Cancer Lett; 2021 Jun; 507():89-96. PubMed ID: 33744389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation.
    Gilson P; Franczak C; Dubouis L; Husson M; Rouyer M; Demange J; Perceau M; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(7):e0219204. PubMed ID: 31265477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.
    Grasselli J; Elez E; Caratù G; Matito J; Santos C; Macarulla T; Vidal J; Garcia M; Viéitez JM; Paéz D; Falcó E; Lopez Lopez C; Aranda E; Jones F; Sikri V; Nuciforo P; Fasani R; Tabernero J; Montagut C; Azuara D; Dienstmann R; Salazar R; Vivancos A
    Ann Oncol; 2017 Jun; 28(6):1294-1301. PubMed ID: 28368441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.
    Moati E; Blons H; Taly V; Garlan F; Wang-Renault SF; Pietrasz D; Didelot A; Garrigou S; Saint A; Pernot S; Taieb J; Laurent-Puig P; Zaanan A
    Int J Cancer; 2020 Aug; 147(4):1185-1189. PubMed ID: 31472013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liquid biopsy for
    Güttlein L; Luca MR; Esteso F; Fresno C; Mariani J; Otero Pizarro M; Brest E; Starapoli S; Kreimberg K; Teves P; Mendoza Bertelli A; R Girotti M; Salanova R; O'Connor JM
    Future Oncol; 2022 Sep; 18(29):3277-3287. PubMed ID: 36004810
    [No Abstract]   [Full Text] [Related]  

  • 26.
    Lastraioli E; Antonuzzo L; Fantechi B; Di Cerbo L; Di Costanzo A; Lavacchi D; Armenio M; Arcangeli A; Castiglione F; Messerini L; Di Costanzo F
    Oncol Lett; 2021 Jan; 21(1):15. PubMed ID: 33240421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
    Pietrantonio F; Vernieri C; Siravegna G; Mennitto A; Berenato R; Perrone F; Gloghini A; Tamborini E; Lonardi S; Morano F; Picciani B; Busico A; Volpi CC; Martinetti A; Battaglin F; Bossi I; Pellegrinelli A; Milione M; Cremolini C; Di Bartolomeo M; Bardelli A; de Braud F
    Clin Cancer Res; 2017 May; 23(10):2414-2422. PubMed ID: 27780856
    [No Abstract]   [Full Text] [Related]  

  • 28. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of KRAS, NRAS and BRAF mutational profile by combination of in-tube hybridization and universal tag-microarray in tumor tissue and plasma of colorectal cancer patients.
    Damin F; Galbiati S; Soriani N; Burgio V; Ronzoni M; Ferrari M; Chiari M
    PLoS One; 2018; 13(12):e0207876. PubMed ID: 30562355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA.
    Hussung S; Follo M; Klar RFU; Michalczyk S; Fritsch K; Nollmann F; Hipp J; Duyster J; Scherer F; von Bubnoff N; Boerries M; Wittel U; Fritsch RM
    J Mol Diagn; 2020 Jul; 22(7):943-956. PubMed ID: 32376474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
    Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
    Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of
    Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A
    J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.
    Lièvre A; Merlin JL; Sabourin JC; Artru P; Tong S; Libert L; Audhuy F; Gicquel C; Moureau-Zabotto L; Ossendza RA; Laurent-Puig P; Ducreux M
    Dig Liver Dis; 2018 May; 50(5):507-512. PubMed ID: 29396127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue.
    Johnston L; Power M; Sloan P; Long A; Silmon A; Chaffey B; Lisgo AJ; Little L; Vercauteren E; Steiniche T; Meyer T; Simpson J
    J Clin Pathol; 2018 Apr; 71(4):336-343. PubMed ID: 28899979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan.
    Awidi M; Ababneh N; Shomaf M; Al Fararjeh F; Owaidi L; AlKhatib M; Al Tarawneh B; Awidi A
    PLoS One; 2019; 14(12):e0226473. PubMed ID: 31881025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.
    Nagakubo Y; Hirotsu Y; Amemiya K; Oyama T; Mochizuki H; Omata M
    BMC Med Genomics; 2019 Nov; 12(1):162. PubMed ID: 31711486
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Sunakawa Y; Nakamura M; Ishizaki M; Kataoka M; Satake H; Kitazono M; Yanagisawa H; Kawamoto Y; Kuramochi H; Ohori H; Nakamura M; Maeda F; Komeno C; Sonezaki T; Takeuchi M; Fujii M; Yoshino T; Tsuji A; Ichikawa W
    JCO Precis Oncol; 2020 Nov; 4():898-911. PubMed ID: 35050760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.